STOCKS TELEGRAPH

Tag: NASDAQ: MCRB

  • Seres Therapeutics Inc. (MCRB) stock plunged in the premarket trading session; here’s why

    It was observed in the last check, that Seres Therapeutics Inc. (MCRB stock) shares had plunged in the premarket trading session. The double-digit plunge had shed-58.09% off of the share price bringing it at $8.73 in pre-market. MCRB stock had closed the previous session on Thursday with a gain of 0.48% at $20.83. The MCRB stock volume traded 0.87 million shares, while in the past 50 days the average trade volume per day was around 0.87 million shares. In the past year up to date, MCRB shares have jumped by 338.53% and in the past week, the MCRB stock moved up by 1.61%. In the past three and six months, the stock has gained 1.66% and shed -17.99% respectively. Furthermore, the company is currently valued at $1.86 billion and has 91.53 million outstanding shares.

    About Seres Therapeutics Inc.

    Seres Therapeutics Inc. is a biotechnology company that specifically focuses on the development, discovery, and licensing of disease-treating therapeutics. The therapeutics is based on a microbiome platform that creates bacterial consortia. The bacterial consortia’s primary function is to interact with the host cells and tissues in a therapeutic way to treat the disease.

    The organization’s lead item up-and-comer is the SER-109, an oral microbiome helpful competitor that has finished Phase III clinical preliminary for the treatment of clostridium difficile disease (CDI). It is likewise creating SER-287 that is in Phase IIb clinical preliminary to treat ulcerative colitis; SER-401, which is in Phase Ib clinical preliminary for use with designated spot inhibitors in patients with metastatic melanoma; and SER-301 that is in the Phase 1b clinical preliminary for the treatment of incendiary entrail sickness. What’s more, the organization participates in the improvement of SER-262 to treat an underlying repeat of CDI; and SER-155, a developed microorganisms microbiome drug intended to forestall mortality because of gastrointestinal contaminations, bacteremia, and join versus have illnesses in immunocompromised patients getting allogeneic hematopoietic undifferentiated cell transplantation and organ transfers.

    The company’s platform and progress allows it to have licensing partnerships with other medical institutions and firms across the industry. It has made these sort of partnerships with Memorial Sloan Kettering Cancer Center and NestecLTd. The company was originally formed in 2010 by the name of Seres Health Inc. which was changed in May 2015. Furthermore, the headquarter of the company lies in Cambridge, Massachusetts.

    MCRB stock is holding a meeting regarding the topline results of the phase 2b trial of ECO-RESET study

    By Easter Time 8:30 am today, the MCRB stock had been hosting a conference call and live audio webcast. This conference was specifically hosted by the management team at Seres Therapeutics Inc. The main reason for hosting this live call and conference is to address the results from the phase 2b ECO-RESET study which had evaluated SER-287 in patients with mild-to-moderate ulcerative colitis (UC). The company provided topline results for this phase 2b study which listed that the Essential endpoint of clinical abatement contrasted with fake treatment was not accomplished; both dosing regimens of SER-287 were for the most part very much endured; open name and support parts of the SER-287 examination will be shut and Microbiome endpoints and examinations expected in the second 50% of 2021.

  • Here’s Top 25 Biotech Stocks For September 2020

    Here’s Top 25 Biotech Stocks For September 2020

    One thing constant in the world is change. As time passes there are many industries that are undergoing changes as they expand their businesses and bring new innovations. One of the industries that are known for their constant change is the biotechnology industry.

    The biotech industry is continuously changing in every aspect of daily existence with new technological breakthroughs and advancements in knowledge. Companies are constantly striving to bring new medicines and vaccines to deal with the diagnosis.

    Let’s have a look at the top 25 biotech companies which are continuously adding new trends in the market:

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) shares were trading up 171.59% at $34.22 at the time of writing on Monday.

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) share price went from a low point around $10.09 to briefly over $37.00 in the past 52 weeks, though shares have since pulled back to $34.22. AIMT market cap has remained high, hitting $2.13B at the time of writing, giving it a price-to-sales ratio of more than 3550.

    If we look at the recent analyst rating AIMT, Cowen initiated coverage on AIMT shares with an Outperform rating. Aimmune Therapeutics recently disclosed it has signed an agreement with Nestle S.A. As per the agreement, Nestle will pay $34.50 per share in an all-cash transaction.

    Akcea Therapeutics Inc. (AKCA) last closed at $18.28, in a 52-week range of $8.00 to $22.79. It has been disclosed yesterday that Ionis Pharmaceutical has bought the 24% shares of Akcea it hasn’t owned earlier for $18.15 per share in cash. This acquisition is one step forward to make a strong and efficient organization that gives benefits to all shareholders.

    Capricor Therapeutics Inc. (NASDAQ: CAPR) Shares headed rising, higher as much as 14.64% after Capricor Therapeutics to Present at The LD 500 Virtual Conference. Capricor market capitalization is 115.11 million. The most recent rating by Maxim Group, on December 26, 2018, is at a Hold.

    Capricor Therapeutics, a clinical-stage biotechnology company has disclosed earlier that the US Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for a Phase 2 clinical trial of CAP-1002 in COVID-19 patients.

    Apellis Pharmaceuticals Inc. (APLS) stock soar by 14.74% to $30.83. The most recent rating by ROTH Capital, on July 20, 2020, is at a Buy. Its stock fluctuated between the 52-weeks low range of $16.85 and a 52-weeks high range of $45.04. It has moved up 82.97% from its 52-weeks low and moved down -31.55% from its 52-weeks high.

    Xeris Pharmaceuticals Inc. (NASDAQ: XERS) rose 10.71% after gaining more than $0.45 on Monday. Xeris, a specialty pharmaceutical company disclosed August 26, 2020, that the Compensation Committee of Xeris’ Board of Directors awarded non-qualified stock options for an aggregate of 500 share of its common stock to 1 new employee under the Inducement Equity Plan of Xeris.

    Xeris share price went from a low point around $1.42 to briefly over $12.29 in the past 52 weeks, though shares have since pulled back to $4.71. It has traded up $231.34% from its 52-weeks low and has traded down -61.72% from its 52-weeks high.

    9 Meters Biopharma Inc. (NASDAQ: NMTR) shares headed rising, higher as much as 7.73%. It has disclosed Monday that it has decided to form the scientific advisory board (SAB). The SAB includes an acclaimed group of six experts in the gastroenterology field with sub-specialties in celiac disease, inflammatory bowel disease (IBD), and functional GI diseases. 9 Meters have gained +0.05 during its trading on Monday. It has moved up 76.17% and moved down -49.46% from its 52-weeks low and high range, respectively.

    VBI Vaccines Inc. (NASDAQ: VBIV) rose 6.77% after gaining more than $0.27 on Monday. VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at EASL 2020. During the presentation, Professor of Paediatrics at the University of Bristol, UK, and principal investigator of the CONSTANT Phase 3 clinical study, Adam Finn, M.D., Ph.D., revealed the encouraging points of hepatitis B antibodies. VBI Vaccines traded up 815.15% from its 52-weeks low and traded down -38.53% from its 52-weeks high.

    CymaBay Therapeutics Inc. (NASDAQ: CBAY) rose 5.37% after gaining more than $0.33 on Monday. It has disclosed the result of Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC). The data presented at electronic presentation showed the safety and efficacy of seladelpar over 1 year of open level treatment. These findings suggest that seladelpar treatment in a high-risk PBC patient population promotes clinically significant improvement.

    BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) rose 4.53% after gaining more than $0.18 on Monday. BioCryst Inc disclosed Monday it has received Orphan Drug Desigantion from FDA for its oral Factor D inhibitor, BCX9930. It is used for the treatment paroxysmal nocturnal hemoglobinuria (PNH). It has moved up as its announced it has received the $44 million  National Institute of Allergy and Infectious Diseases (NIAID). This amount is awarded to BCRX by NIAID to support the development of galidesivir.

    ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Shares headed rising, higher as much as 4.24%. The most recent rating by Raymond James, on August 25, 2020, is at an Outperform. ACADIA Inc has announced earlier that it has bought CerSci Therapeutics.

    Immunomedics Inc. (IMMU) stock soar by 6.37% to $44.56. The most recent rating by Barclays, on May 05, 2020, is at an Overweight. Immunomedics stock has fluctuated between the 52-weeks low and high range of $8.80-$44.91, respectively.

    Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) last closed at $114.22, in a 52-week range of $72.67 to $121.50. Analysts have a consensus price target of $141.47.

    Seres Therapeutics Inc. (NASDAQ: MCRB) stock soar by 8.21% to $26.49.  It has moved upward 951.19% from its 52-weeks low and moved down -19.73% from its 52-weeks high. The most recent rating by Piper Sandler, on August 18, 2020, is at an Overweight.

    Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) last closed at $29.51 after gaining +2.54 on Monday. It has a 52-week range of $12.99 to $27.97. It has moved up 127.17% and 5.51% from its 52-weeks low and high, respectively. Analysts have a consensus price target of $32.88.

    Geron Corporation (NASDAQ: GERN) Shares headed rising, higher as much as 6.22%. The most recent rating by Stifel, on August 03, 2020, is at a Buy.

    Sesen Bio Inc. (NASDAQ: SESN) rose 6.19% after gaining more than $0.06 on Monday. SESN’s stock has changed between the 52-weeks low range of $0.37 and a high range of $1.52. It has moved up and moved down 178.38%, -33.12% from its 52-weeks low and high, respectively.

    Kadmon Holdings Inc. (NYSE: KDMN) last closed at $5.00, in a 52-week range of $2.04 to $5.50. It has traded up 145.10% from its 52-weeks low and traded down -9.09% from its 52-weeks high. Looking at its liquidity, its current ratio is 6.20.

    Evofem Biosciences Inc. (EVFM) stock soar by 6.07% to $3.32 after Evofem Biosciences to Participate in Four Upcoming Investor Conferences. The most recent rating by Morgan Stanley, on August 20, 2020, is at an Equal-weight.

    MacroGenics Inc. (NASDAQ: MGNX) Shares headed rising, higher as much as 6.01%. The most recent rating by Citigroup, on August 03, 2020, is at a Neutral.

    Iovance Biotherapeutics Inc. (NASDAQ: IOVA) last closed at $33.33, in a 52-week range of $17.67 to $41.49. Analysts have a consensus price target of $47.08.

    Surface Oncology Inc. (NASDAQ: SURF) stock soar by 5.01% to $6.50. The most recent rating by Wedbush, on August 28, 2020, is at an Outperform.

    Fortress Biotech Inc. (NASDAQ: FBIO) Shares headed rising, higher as much as 4.63% after LD Micro — 360 Companies Set to Present this Week. The most recent rating by B. Riley FBR, on December 18, 2019, is at a Buy.

    Synthetic Biologics Inc. (SYN) last closed at $0.64, in a 52-week range of $0.25 to $0.75. It has moved up 153.17% from its 52-weeks low and moved down -14.87% from its 52-weeks high.

    Zogenix Inc. (NASDAQ: ZGNX) stock soar by 4.37% to $23.67. The most recent rating by Raymond James, on August 25, 2020, is at an Mkt perform. ZGNX has traded up and down 42.16% and -58.63% from its 52-weeks low and high range.

    Dynavax Technologies Corporation (NASDAQ: DVAX) rose 4.18% after gaining more than $0.24 on Monday. Dynavax to Present at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference.

     

  • Top Performing Biotech Stocks amidst Mixed Market Sentiment

    Top Performing Biotech Stocks amidst Mixed Market Sentiment

    The markets are in mixed territory this afternoon. The NASDAQ is down due to a sharp drop in big tech stocks that make up a huge percentage of the index. On the other hand, the Dow and the S&P 5O0 are showing signs of strength. Besides big-tech price action, markets are still digesting the executive orders that President Trump signed over the weekend.

    The package includes a $400 unemployment payout that is only expected to last for a month. President Trump also deferred payroll taxes to the year’s end, but analysts are unsure that people will be willing to spend unless there is a change in the tax laws.

    Nonetheless, the executive order gave a boost to the economy, even as markets look to congress for a more detailed package. Despite the mixed signals that the markets are sending, there are stocks that are in huge gains at the moment.  Some of the top gainers this afternoon are biotech stocks that are driven by positive product development news. Below are some of the biggest movers in the day:

    Omeros Corporation [NASDAQ: OMER]

    Omeros Corporation has gained exponentially this afternoon and though volatile, it is still up by over 48%. The huge gains come after the company announced that it got a 100% recovery and survival rate for its COVID-19 treatment for patients with Acute Respiratory Distress Syndrome. The company announced that all 6 patients that took part in the study and needed ventilators before the treatment, survived and were discharged fully recovered.

    The company further stated that the treatment, called Narsoplimab, had led to an improvement in outcomes on all the markers that it was assessed. The company also stated that it was holding talks with different agencies of the American government for accelerated manufacture of this treatment.  The company is specifically holding discussions with the Department of Health and Human Services, the Biomedical Advanced Research Development Authority, and the National Institutes of Health Accelerating COVID-19 Therapeutic Interventions and Vaccines.

    Seres Therapeutics Inc. [NASDAQ: MCRB]

    Seres Therapeutics Inc. is another top performer this afternoon and is up by over 300%. This follows the company’s announcement that its late-stage drug test for its colon infections treatment was a success.  The company was testing for its treatment called SER-109. This is an oral treatment for a C. difficile, a dangerous lung treatment.  CEO Eric Shaff said that the FDA would likely find the results clinically meaningful.

    Xtant Medical Holdings Inc. [NYSE: XTNT]

    This is another top performer this afternoon and is up by over 85%. This follows the company’s announcement that it was restructuring its debts. The company announced that it had entered into an agreement with its lenders on a plan that will see it have a better capital structure, and access growth opportunities in the future.